Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations

<div>Treatment with MLN2238/ixazomib promotes apoptosis, potentially through the UPR pathway. Cells were treated for 0, 24, or 48 h with MLN2238/ixazomib and cell lysates analyzed by western blotting with the indicated antibodies (<i>α</i>-tubulin served as a loading control).</div>

Disease Markers

fig4

Figure 4

Figure 4: Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations 